UPDATE: See June 23, 2020 article here describing the notable changes. See our article here regarding the final October 2020 Guidelines. On November 23, Innovative Medicines Canada and a number of research-based pharmaceutical companies commenced an application for judicial review of the final Guidelines.
The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.
An industry webinar on the revised draft Guidelines is scheduled for June 29, 2020 from 1:30 – 4:30pm. A public webinar is scheduled for July 8, 2020 from 1:30 to 4:30pm.
The accompanying backgrounder document is to be released by the PMPRB the week of June 22.
Our more detailed reporting of the substantial changes to the first draft of the Guidelines, which were published in November of 2019, will soon follow (see here).
Should you have any questions on the foregoing, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.